Actively Recruiting
Study of Two Intravenous Infusions of AION-301 Versus Placebo in Adults Aged 35 to 75 With Stage 3 Chronic Kidney Disease
Led by AION Healthspan, Inc. · Updated on 2026-04-01
36
Participants Needed
2
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and effects of two intravenous infusions of AION-301 in adults aged 35 to 75 with Stage 3 Chronic Kidney Disease CKD. The trial aims to determine if AION-301 causes any adverse medical problems, reduces CKD symptoms, and slows disease progression compared to a placebo. This study is a randomized, triple-blinded clinical trial sponsored by AION Healthspan, Inc., focusing on important safety and efficacy questions for people with CKD stage 3. Participants will receive two infusions of either AION-301 or a placebo on Day 0 and Day 4. They will also take oral vitamins provided at the clinic and at home for 90 days. The study includes at least 9 clinic visits over 6 months for health checkups and tests, with the possibility of up to 12 visits over 24 months for ongoing monitoring and assessments. During the study, participants will undergo various evaluations including safety assessments of adverse events up to 90 days, and efficacy measures related to kidney function and disease progression up to two years. Researchers will monitor kidney risk profiles and other health indicators. The total participation time may span from several months to two years with regular follow-ups to track health status and treatment effects.
CONDITIONS
Brief Title
A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)
Research Team
G
Giacomo Lanzoni, PHD
D
Desa Rae E Stanton-Pastore, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here